Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
HOWL Total Current Liabilities
All obligations due within one year.
Werewolf Therapeutics, Inc.NASDAQ: HOWL
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities falls 48.2% from a year ago
Total current liabilities stood at $7.86M at the end of Q2 FY2026, down 48.2% from a year earlier and down 79.6% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.
Context
- Total current liabilities amounted to 32.6% of total assets at the end of Q2 FY2026, up 16.2 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -48.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 36.15M USD
- Year-over-year change
- +138.1%
- 4-year CAGR
- +32.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.15M | +138.1% |
| FY2024 | 2024-12-31 | 15.18M | -21.7% |
| FY2023 | 2023-12-31 | 19.38M | -19.2% |
| FY2022 | 2022-12-31 | 23.99M | +102.0% |
| FY2021 | 2021-12-31 | 11.87M | — |
Total Current Liabilities vs competitors
How HOWL compares with its peers on the latest reported figures
- HOWL's Jun 2026 total current liabilities of $7.86M is the 6th highest of the 8 companies compared; the peer median is $16.95M.
- Its year-over-year change of -48.2% is the 7th highest of 8, against a peer median of -23.1%.
- Total current liabilities amounts to 32.6% of total assets for HOWL, versus a peer median of 23.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $38.88M | +56.6% | +32.4% | 177.6% | |
| Mar 2026 | $25.18M | -23.1% | +22.4% | 211.5% | |
| Mar 2026 | $18.3M | +11.3% | +3.0% | 10.8% | |
OSTXOS Therapies Incorporated | Mar 2026 | $16.95M | +379.4% | +24.2% | 232.3% |
| Mar 2026 | $11.78M | -24.8% | -6.8% | 21.0% | |
| Jun 2026 | $7.86M | -48.2% | +14.6% | 32.6% | |
| Mar 2026 | $7.39M | -52.3% | +5.3% | 23.9% | |
| Mar 2026 | $5.39M | -32.0% | -8.3% | 20.9% | |
| Peer median (excluding HOWL) | $16.95M | -23.1% | +5.3% | 23.9% | |
Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 157.53M | 129.32M | 134.34M | 111M | 57.95M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 6.93M | 1.35M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 100K | 3.96M | 2.68M | 2.07M | 635K |
| Total Current Assets | 161.07M | 140.2M | 138.37M | 113.07M | 58.59M |
| Property, Plant & Equipment (Net) | 16.33M | 17.45M | 14.85M | 12.32M | 9.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 1.21M | 21.02M | 1.22M | 901K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.86M | 1.38M | 594K | 320K | 5K |
| Total Non-current Assets | 18.18M | 20.05M | 36.46M | 13.86M | 10.81M |
| Total Assets | 179.25M | 160.25M | 174.83M | 126.93M | 69.4M |
| Account Payables | 2.04M | 1.22M | 1.34M | 3.04M | 754K |
| Short-term Debt | 0 | 0 | 6.67M | 0 | 1.75M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 6.53M | 907K | 0 | 0 |
| Other Current Liabilities | 163K | 11.02M | 3.63M | 3.62M | 33.64M |
| Total Current Liabilities | 11.87M | 23.99M | 19.38M | 15.18M | 36.15M |
| Long-term Debt | 0 | 0 | 32.66M | 26.1M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1.32M | 433K | 2.83M | 759K |
| Total Non-current Liabilities | 14.59M | 13.92M | 44.08M | 38.36M | 8.44M |
| Total Liabilities | 26.46M | 37.91M | 63.46M | 53.54M | 44.59M |
| Common Stock | 2K | 3K | 4K | 5K | 5K |
| Retained Earnings | (252.9M) | (306.71M) | (344.07M) | (414.59M) | (475.41M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 152.79M | 122.34M | 111.37M | 73.39M | 24.81M |
| Total Debt | 15.66M | 14.68M | 51.92M | 37.09M | 9.44M |
| Net Debt | (141.87M) | (114.63M) | (82.42M) | (73.91M) | (48.52M) |
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.